Validation of a novel cognitive-functional outcome measure optimized for early Alzheimer’s Disease: Evidence from the VIVA-MIND trial
Practically significant differences in the efficiency of clinical trials in early AD may be realized by the choice of clinical outcome measure and weighting scheme. Although further verification is needed, we replicate a previous finding that the CFC2 may outperform the CDR-SB in the early AD population.
Authors
- Carolyn Revta
- Antje Meyer (ORCID: https://orcid.org/0000-0003-1675-4512)
- Andrew MacKelfresh
- Christine Wenzkowski
- Tanja Wassmann
- Sylvia Schell-Mader
- Jasmin Duehring
- Michael Schaeffer
- Diane M. Jacobs
- Steven D. Edland
- Howard H. Feldman
- David P. Salmon
Institutions
- University of California San Diego (US)
- Alzheimer’s Disease Neuroimaging Initiative (US)
Publication Details
- Journal
- The Journal of Prevention of Alzheimer s Disease
- Published
- 2026-03-13
- DOI
- https://doi.org/10.1016/j.tjpad.2026.100531
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00